Patent intelligence · US
US 9926315
Triazolopyridine compounds and methods for the treatment of cystic fibrosis
Triazolopyridine compounds and methods for the treatment of cystic fibrosis
Patent details — US 9926315
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 27, 2018
- Expiration
- Mar 22, 2038
- Applicant
- Flatley Discovery Lab, LLC
- Claims
- 9
- CPC classes
- A61K, A61K31/4196, A61K31/437, A61K31/4439
Quick answer
US 9926315 (Triazolopyridine compounds and methods for the treatment of cystic fibrosis) is held by Flatley Discovery Lab, LLC. Status: granted. Granted Mar 27, 2018. Expires Mar 22, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Flatley Discovery Lab, LLC
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K31/4196, A61K31/437, A61K31/4439, A61K31/444, A61K31/4545
More from Flatley Discovery Lab, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12427173
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
granted -
US 12428415
Matriptase 2 inhibitors and uses thereof
granted -
US 12421236
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
granted -
US 12420085
Synergistic therapies for inter vertebral disc degeneration
granted -
US 12421231
Azaindole derivatives and their use as ERK kinase inhibitors
granted -
US 12403069
Adapter for use in a planetary mixer
granted -
US 12398179
Nanomolar peptides and derivatives to differentially modulate ephrin receptors
granted -
US 12396924
Adapter for use in a planetary mixer
granted
Frequently asked questions
What is US patent 9926315?
US 9926315 (Triazolopyridine compounds and methods for the treatment of cystic fibrosis) is held by Flatley Discovery Lab, LLC. Status: granted. Granted Mar 27, 2018. Expires Mar 22, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9926315?
Flatley Discovery Lab, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 706 pharmaceutical patents for this assignee.
When does US 9926315 expire?
Our index shows an expiration date of Mar 22, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.